This award supports product-driven research focused on developing new therapeutics and diagnostics for Lyme disease and other tick-borne diseases. Therapeutic projects should be in early or preclinical stages aiming at drug discovery, while diagnostic projects should propose methods ready for clinical use. The goal is to reduce disease burden and enhance patient quality of life.
Open to any type of entity, with possible clarifications in additional eligibility information. No specific restrictions stated.
